4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents

Clinical Indications & Resuscitative Objectives

Rapid Sequence Intubation (RSI) is the cornerstone airway management strategy in emergency medicine and critical care resuscitation. It is defined as the virtually simultaneous administration of a potent sedative-hypnotic induction agent and a rapidly acting neuromuscular blocking agent (NMBA) to induce immediate unconsciousness and flaccid motor paralysis. The primary clinical objective is to achieve optimal conditions for endotracheal intubation within 45 to 60 seconds while minimizing gastric insufflation, regurgitation and aspiration in an unfasted emergency patient. Classic RSI avoided bag-mask ventilation during apnea, but the PreVent trial (2019) showed that gentle bag-mask ventilation between induction and laryngoscopy reduced severe hypoxemia without increasing aspiration, so many clinicians now ventilate patients at risk of desaturation.

Emergency airway intervention is indicated across three distinct clinical scenarios:

1. Failure of Airway Maintenance or Protection: Loss of protective pharyngeal reflexes, depressed consciousness (Glasgow Coma Scale [GCS] ≤8), massive upper gastrointestinal hemorrhage, severe maxillofacial trauma, or active pooling of secretions.
2. Failure of Oxygenation or Ventilation: Severe hypoxemic respiratory failure refractory to high-flow nasal cannula or noninvasive positive pressure ventilation (e.g., severe ARDS, multifocal pneumonia), or severe acute hypercapnic respiratory acidosis with respiratory muscle exhaustion.
3. Anticipated Clinical Deterioration: Clinical trajectories pointing toward imminent airway loss, including progressive angioedema, expanding neck hematomas, thermal inhalation burns with stridor, severe sepsis requiring invasive ventilation to decrease the work of breathing, or polytrauma requiring immediate operative intervention.

Physiological Hazards of Airway Instrumentation

Laryngoscopy and passage of an endotracheal tube (ETT) are intensely noxious mechanical stimuli. Forceful instrumentation of the base of the tongue, epiglottis, and vocal cords stimulates rich somatic and visceral afferents carried by the glossopharyngeal (cranial nerve IX) and vagus (cranial nerve X) nerves. In an inadequately blunted patient, this sensory input activates the vasomotor centers of the brainstem, triggering the Reflex Sympathetic Response to Laryngoscopy (RSRL).

The RSRL causes a massive surge in endogenous catecholamines (norepinephrine and epinephrine), resulting in acute hypertension, tachycardia, and increased systemic vascular resistance. In vulnerable patient populations, these acute hemodynamic perturbations can have catastrophic consequences:

• Acute Neurovascular Emergencies: In aneurysmal subarachnoid hemorrhage (aSAH), acute intracerebral hemorrhage (ICH), or severe traumatic brain injury (TBI), an abrupt spike in mean arterial pressure (MAP) elevates intracranial pressure (ICP) and increases transmural aneurysm stress, precipitating fatal aneurysm re-rupture, hematoma expansion, or brainstem herniation.
• Cardiovascular Crises: In acute aortic dissection (Stanford Type A or B), the sudden rise in myocardial contractility and blood pressure accelerates the rate of aortic pressure change ($\Delta P / \Delta t$), propagating dissection tears. In acute coronary syndromes (ACS), tachycardia dramatically increases myocardial oxygen consumption ($MVO_2$) while shortening diastolic coronary perfusion time.
• Reactive Airway Disease: Direct stimulation of the tracheobronchial tree triggers parasympathetic cholinergic efferents that induce severe, life-threatening reflex bronchoconstriction in patients with acute status asthmaticus or severe chronic obstructive pulmonary disease (COPD).

---

The Seven Ps of RSI Operational Timeline

Emergency RSI follows an operational checklist structured around the Seven Ps, establishing a synchronized countdown from ten minutes prior to intubation through post-intubation stabilization:

Physiological Foundations of Preoxygenation & Apneic Oxygenation

Preoxygenation achieves 'denitrogenation' of the lungs. Ambient air is composed of approximately 78% nitrogen and 21% oxygen. During 3 to 5 minutes of tidal volume breathing at 100% $FiO_2$ (or 8 vital capacity breaths), alveolar nitrogen is washed out and replaced with oxygen, transforming the patient's functional residual capacity (FRC)—approximately 30 mL/kg—into an internal oxygen reservoir.

In a healthy 70-kg adult, this reservoir provides approximately 2,000 mL of oxygen, extending the safe apnea time (the duration of apnea before pulse oximetry falls below 90%) to 8 to 10 minutes. However, in critically ill emergency patients, safe apnea time is profoundly shortened (often to under 2 to 3 minutes) due to:

• Increased metabolic oxygen consumption ($VO_2$) from sepsis, fever, or agitation.
• Reduced FRC from obesity, supine positioning, abdominal distension, or chest wall trauma.
• Significant intrapulmonary shunt (e.g., severe pneumonia, pulmonary contusion, ARDS) where non-ventilated alveoli perfuse deoxygenated blood directly into systemic circulation.

---

Pretreatment Pharmacotherapy: The LOAD Regimen & Evidence Base

Pretreatment medications are administered strictly 3 minutes prior to induction ($T-3$ minutes). This 3-minute interval ensures that the agent crosses the blood-brain barrier and achieves peak effect-site receptor concentration precisely when laryngoscopy and intubation occur. The historical mnemonic LOAD categorizes the four potential pretreatment classes:

                          PRETREATMENT PHARMACOTHERAPY (LOAD)
  ┌─────────────────────────────────────────────────────────────────────────────────┐
  │ L - Lidocaine (1.5 mg/kg IV)         │ Blunts bronchospasm & cough reflex       │
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ O - Opioid / Fentanyl (3 mcg/kg IV)  │ Blunts reflex sympathetic response (RSRL)│
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ A - Atropine (0.02 mg/kg IV)         │ Prevents vagal reflex bradycardia in peds│
  ├─────────────────────────────────────────────────────────────────────────────────┤
  │ D - Defasciculating NMBA (Obsolete)  │ Historically prevented fasciculations    │
  └─────────────────────────────────────────────────────────────────────────────────┘

1. Fentanyl (Opioid Pretreatment)

• Dose & Route: 3 mcg/kg IV administered slowly over 30 to 60 seconds at $T-3$ minutes.
• Pharmacodynamics: Highly lipophilic, synthetic $\mu$-opioid receptor agonist with an onset of 1 to 2 minutes and duration of 30 to 60 minutes. It acts centrally within the brainstem to suppress sympathetic outflow, blunting the reflex surge of epinephrine and norepinephrine triggered by laryngoscopy.
• Primary Clinical Indications:
  • Acute intracranial pathology: Aneurysmal subarachnoid hemorrhage (aSAH), acute intracerebral hemorrhage (ICH), severe traumatic brain injury (TBI) with suspected intracranial hypertension.
  • Acute cardiovascular disasters: Stanford Type A or Type B aortic dissection, acute myocardial infarction, unstable angina.
• Cautions & Pitfalls: Fentanyl blunts compensatory sympathetic tone. In patients with unresuscitated hypovolemic, hemorrhagic, or septic shock, a 3 mcg/kg dose can precipitate severe hypotension or circulatory collapse. Rapid IV push boluses of high-dose fentanyl can induce chest wall and glottic rigidity ('wooden chest syndrome'), severely impeding rescue bag-valve-mask ventilation.

2. Lidocaine

• Dose & Route: 1.5 mg/kg IV (maximum 100 mg) administered at $T-3$ minutes.
• Pharmacodynamics: Class Ib antiarrhythmic and local anesthetic that reversibly blocks voltage-gated sodium channels in airway mechanoreceptors and central cough reflex arcs. It suppresses airway sensory nerve signaling, attenuates reflex bronchoconstriction, and modestly blunts increases in ICP.
• Primary Clinical Indications: Severe reactive airway disease (acute status asthmaticus, severe COPD exacerbation) undergoing emergency intubation. Historically advocated for acute traumatic brain injury; however, contemporary neurocritical guidelines regard the evidence for ICP reduction as weak and equivocal.
• Contraindications: High-grade atrioventricular (AV) block, severe bradycardia, cardiogenic shock, or known hypersensitivity to amide-type local anesthetics.

3. Atropine

• Dose & Route: 0.02 mg/kg IV; maximum single dose 0.5 mg IV in children (1 mg in adolescents and adults). When atropine is used as premedication for emergency intubation, AHA PALS guidance (2015, carried forward) states that a dose of 0.02 mg/kg with no minimum dose may be considered. The traditional 0.1 mg minimum still appears in some bradycardia references.
• Pharmacodynamics: Competitive antagonist at muscarinic acetylcholine receptors. It blocks vagal parasympathetic stimulation to the sinoatrial (SA) and atrioventricular (AV) nodes.
• Primary Clinical Indications:
  • Pediatric intubation in infants $<1$ year of age receiving succinylcholine (infants possess high baseline vagal tone and immature sympathetic innervation, making them exquisitely prone to profound reflex bradycardia during laryngoscopy).
  • Children $<5$ years receiving a second dose of succinylcholine.
  • Patients experiencing symptomatic bradycardia during airway manipulation.
• The Paradoxical Bradycardia Debate: Very small atropine doses were long thought to cause paradoxical bradycardia by blocking presynaptic $M_1$ autoreceptors, which is why a 0.1 mg minimum was taught. Pediatric data did not support a minimum dose for intubation premedication, and AHA PALS guidance dropped it for that use. Routine atropine premedication for every pediatric intubation is not recommended; reserve it for children at higher risk of bradycardia, such as young infants and those receiving a second dose of succinylcholine.

4. Defasciculating Non-Depolarizing NMBAs (Historical Practice)

• Regimen: 10% of a standard intubating dose of a non-depolarizing NMBA (e.g., Rocuronium 0.06 mg/kg IV or Vecuronium 0.01 mg/kg IV) administered 3 minutes prior to succinylcholine.
• Historical Rationale: Theorized to occupy motor endplate receptors, preventing the visible muscle fasciculations caused by succinylcholine, which were believed to cause postoperative myalgias and spike ICP, intraocular pressure (IOP), and intragastric pressure.
• Contemporary Evidence: Defasciculation has been largely abandoned in modern emergency medicine. Rigorous clinical trials demonstrate that succinylcholine-induced fasciculations do not produce clinically meaningful elevations in ICP or adverse neurological outcomes. Furthermore, administering a defasciculating dose causes distressing partial paralysis, diplopia, and severe dyspnea in an awake, anxious patient. If succinylcholine fasciculations or hyperkalemia are a clinical concern, the contemporary evidence-based solution is to utilize high-dose rocuronium (1.2 mg/kg IV) rather than complex defasciculating regimens.

---

Pretreatment Agent Comparative Matrix

---

Worked Clinical Case & Practice Pearls

Clinical Vignette

A 54-year-old female (actual weight 70 kg, height 5'6") presents to the emergency department with a sudden-onset, catastrophic 'thunderclap' headache, vomiting, and rapidly declining mental status. On examination, she is moaning incomprehensibly with non-purposeful withdrawal to painful stimuli (GCS 7). Vital signs: blood pressure 218/118 mmHg, heart rate 108 bpm, respiratory rate 12 breaths/min, and $SpO_2$ 93% on room air. Non-contrast cranial CT reveals diffuse subarachnoid hemorrhage with intraventricular extension (Hunt-Hess Grade 3, modified Fisher Grade 4) secondary to a suspected ruptured anterior communicating artery aneurysm. The emergency team prepares for immediate RSI to secure the airway.

Pharmacotherapeutic Care Plan

1. Preoxygenation ($T-5$ to $T-0$): Apply 100% $FiO_2$ via non-rebreather mask at flush rate ($>15$ L/min) combined with continuous nasal cannula at 15 L/min for apneic oxygenation.
2. Pretreatment Selection & Dosing ($T-3$):
   • Target Physiological Goal: Completely blunt the RSRL to prevent an acute blood pressure surge that would increase transmural aneurysm pressure and trigger catastrophic rebleeding.
   • Drug & Calculation: Fentanyl 3 mcg/kg IV $\times$ 70 kg = 210 mcg IV.
   • Administration Technique: Administer 200 mcg IV push slowly over 60 seconds exactly 3 minutes prior to induction.
3. Induction & Paralysis ($T-0$): Etomidate 0.3 mg/kg IV (20 mg) plus Rocuronium 1.2 mg/kg IV (84 mg, rounded to 90 mg).
4. Outcome: Laryngoscopy is performed smoothly at $T+50$ seconds; the patient's blood pressure remains stable at 145/85 mmHg throughout instrumentation without reflex tachycardia or hypertensive spiking.